1%), anemia (6% vs.
<1%), dyspnea (4% vs.
1%), hyperglycemia (4% vs.
<1%), fatigue (4% vs.
1%), and pneumonitis (3% vs.
0%).OS differences were not significant after further follow-up.[28] At the interim analysis, median PFS was 6.9 months for everolimus plus exemestane and 2.8 months for placebo plus exemestane (HR, 0.43; 95% CI, 0.35â€“0.54;P< .001).
The addition of everolimus to exemestane was more toxic than was placebo plus exemestane, with the most-common grade 3 or 4 adverse events being stomatitis (8% vs.
1%), anemia (6% vs.
<1%), dyspnea (4% vs.
1%), hyperglycemia (4% vs.
<1%), fatigue (4% vs.
1%), and pneumonitis (3% vs.